 | 10th - 12th May 2010, London, UKDuring the period 2008-2013, the most important development in influenza vaccines, will be the diversification of influenza manufacturing. New cell-based technologies will be used, and eventually replace, existing egg-based manufacturing methods. Many cell-culture vaccines are being developed under grants from the US government. |
|
 | 17th - 19th March 2010, BSG House, London, UKPharmacovigilance is timely, vital and here to stay. It is becoming ever more important for pharmaceutical companies as the public and legislative pressure to ensure drug safety increases every day. Visiongain's 5th Annual Pharmacovigilance conference will be an eye opener to many different elements including the regulatory and legislative framework, risk management, PSUR, live licensing, in drug safety and surveillance. |
|
 | 10th - 11th March 2010, BSG House, London, UKThe respiratory disorder market is highly competitive and brings in high revenues. The principal drivers are the increase in disease prevalence and the high economic cost of these diseases. With an increasing patient population and high-profile disorders, this market will continue to grow in the foreseeable future. |
|
 | 24th - 26th February 2010, Boston, USAWithout lyophilisation, nearly 60% of biopharmaceuticals including plasma, vaccines and antibodies could not be commercially available. With a greater trend to outsource manufacturing and more of biologicals requiring freeze-drying, this $1.5bn market is set to maintain its year-on-year double digit growth. |
|
 | 28th - 29th January 2010, BSG Conference Centre, London, UKAdvances in recombinant antibodies have impact on a range of therapy areas, such as oncology, CNS, infectious and inflammatory diseases. With an expert line-up of speakers, Visiongain's 3rd Annual Recombinant Antibodies Conference is an ideal forum for industry and academia alike. This 2-day event will explore novel applications of antibodies, recent advances in antibody engineering and the latest clinical developments. |
|
 | 3rd - 4th March 2010, London, UKPharmaceutical and biopharmaceutical companies are under severe pressure to improve product pipelines, accelerate time to market, and improve margins on existing product, while maintaining strict adherence to quality principles and regulatory requirements. It is imperative that pharmaceutical and biotech companies address these business challenges to stay competitive, increase revenue, enhance profit, and reduce the risk of noncompliance. |
|
 | 2nd - 4th March 2010, Boston, USABiologics constitutes a major share of expenditure in the USA and globally. It is one of the fastest growing sectors of the pharmaceutical industry which corresponds to over 15% of the total pharmaceutical market. There is a large and potentially lucrative demand for lower cost biological drugs worldwide. With favourable regulatory developments, the biosimilar sector should pick up significantly, however, forming an important developing pharma market. |
|
 | 4th - 5th February 2010, BSG House, London, UKBiobanking is changing rapidly. Biobanks are playing a vital role in the today's research and development in the fields of drug discovery and bioscience. The biobanking sector is expanding at a tremendous rate in recent years and has also been facing many legal, financial, ethical, scientific challenges. |
|
 | 25th - 26th January 2010, BSG Conference Centre, London, UKSmoking cessation is among the most dynamic markets within the pharma, biotech and healthcare sector, and expected to grow despite the current economic times. According to visiongain's Smoking Cessation 2009-2024 report, the evolution of NRTs - including neuroreceptor modulators, enzyme inhibitors and therapeutic vaccines - will push worldwide sales of smoking cessation drugs to $1.5 billion by 2010, with majority of revenues coming from the NRTs. |
|
 | 9th - 10th November 2009, BSG Conference Centre, London, UK2009's financial turmoil has had a great impact on the pharmaceutical and biotech industry. Pricing and reimbursement remains one of the most notable issues in the globalized market. Pharmaceutical and biotech companies are realigning their pricing and reimbursement strategies, and taking cost containment measures to maintain the growth and profitability. Adding to our successful series of P&R conferences in the UK and USA, we are happy to unveil the much awaited Pharmaceutical Pricing and Reimbursement Summit. |
|
 | Attenuating the progression of hyperglycaemia, dyslipidaemia and diabetic retinopathy21st - 22nd January 2010, BSG House, London, UKSet to double from $32 to $64bn over the next 15 years, the global diabetes market is set for stellar growth as changing demographics and new therapies begin entering the clinic. |
|
 | 10th - 11th February 2010, BSG House, London, UKDrug delivery continues to be increasingly important sector in the pharmaceutical industry and has undergone rapid growth in the last few years. Drug delivery technologies are driving growth of pharmaceutical companies and boosting their revenue by extending the product profitable lifecycle through new formulations, combinations and repositioning. The predominant focus of this conference will be in advancements being made in the drug delivery technologies and understanding the regulatory and legal issues faced by the them. |
|
 | 7th - 8th December 2009, BSG House, London, UKWith more targets, more investment and more oppportunity than ever, vaccine technology is among the most dynamic in biomedicine today. Advances in reverse vaccinology, computer-aided biotechnology and disposable technologies are revolutionising R&D for infectious disease, paediatric and cancer therapies. Allied with new developments in formualtion, informatics and process development, the market will see growth of over 300% between 2009 and 2023. |
|
 | 3rd - 4th December 2009, BSG House, London, UKDermatology is one of the most promising sectors within the global pharmaceutical market. It has witnessed remarkable sales revenues of over $18bn in 2007, and will expand significantly in the next 10 years. Skin infections and disorders such as acne, psoriasis and dermatitis remain major revenue generators for the pharmaceutical and biotech companies. The dermatology market will regain 3.5% growth by 2010, with the development of anti-psoriasis, acne and dermatitis products and treatments (Source: visiongain). Our conference will focus on the advances and innovations in novel drug delivery, therapeutic skin treatments and anti-ageing products, primarily in the developing countries. |
|
 | 11th - 12th November 2009, BSG House, London, UKWell planned, executed and managed stability studies are critical for understanding data generated during clinical trials. Stability testing is an expensive part of product development, but conducted efficiently, it can save money in latter parts of the lifecycle. Visiongain's 3rd Annual Stability Testing conference will examine developments in technology for stability assessment. As part of this 2-day event, leading authorities will assess the application and limitations of various analytical and statistical methods, as well as study design. Participants will be provided with a reliable evaluation of the principles and techniques associated with the stability testing of biologics and new pharmaceutical products. |
|
 | 30th - 31st March 2010, BSG House, London, UKRegenerative medicine is set to revolutionise healthcare as stem cell, tissue engineering, gene therapy and materials science come together to transform patient treatment. Bringing you the latest in translational applications from leading experts, don’t miss this exceptional showcase of medical innovations in this fast-moving field. |
|
 | 16th - 18th November 2009, BSG House, London, UKThe recent surge in contract manufacturing landscape is influencing huge challenges and opportunities in the global pharmaceutical market. The highly competitive nature of the industry has been driving pharma and biotech companies to set up off-shoring alliances with emerging markets to minimise costs and maximise profits. |
|
 | 19th - 21st October 2009, BSG Conference Centre, London, UKThe biological drug market is one of the fastest growing sectors of the pharmaceutical industry which corresponds to over 15% of the total pharmaceutical market. However, due to the patent expiry of many drugs, and increasing pressure from government, insurers and patient advocacy groups to reduce expenditure a number of opportunities for biosimilars have been created. |
|
 | 14th - 15th October 2009, BSG House, LondonBreakthroughs in pain therapy have been rare in the past 50 years, but there is increasing hope that advances in multiple areas of research could lead to the introduction of much-needed novel and more effective analgesics. Modern lifestyles and an aging population will lead the global pain market, worth $35.6bn in 2009, to increase in value by over 50% to $55.2bn by 2023. |
|
 | 1st - 2nd October 2009, BSG Conference Centre, London UKThe current market of prefilled syringes is in the range of 2 - 2.5 billion syringes. The growth rate is to be expected to remain at a high level of more than 10% annually due to a number of factors such as greater medication safety and increased convenience from using a prefillable device. However, there are some challenges and potential threats to syringe and needle supplies manufacturers. |
|
